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Cucurbitacin E, a tetracyclic triterpenes compound extracted from cucurbitaceous plants, has been shown to exhibit anticancer
and anti-inﬂammatory activities. The purpose of this study was to elucidate whether cucurbitacin E promotes cell cycle arrest
and induces apoptosis in T24 cells and further to explore the underlying molecular mechanisms. The eﬀects of cucurbitacin E on
T24 cell’s growth and accompanied morphological changes were examined by MTT assay and a phase-contrast microscope. DNA
content, mitochondrial membrane potential (ΔΨm) and annexin V/PI staining were determined by ﬂow cytometry. The protein
levels were measured by Western blotting. Our results demonstrated that cucurbitacin E-induced G2/M arrest was associated with
a marked increase in the levels of p53, p21 and a decrease in phospho-signal transducer and activator of transcription 3 (STAT3),
cyclin-dependent kinase 1 (CDK1) and cyclin B. Cucurbitacin E-triggered apoptosis was accompanied with up-regulation of
Fas/CD95, truncated BID (t-BID) and a loss of ΔΨm, resulting in the releases of cytochrome c, apoptotic protease activating factor
1 (Apaf-1) and apoptosis-inducing factor (AIF), and sequential activation of caspase-8, caspase-9, and caspase-3. Our ﬁndings
provided the ﬁrst evidence that STAT3/p53/p21 signaling, Fas/CD95 and mitochondria-dependent pathways play critical roles in
cucurbitacin E-induced G2/M phase arrest and apoptosis of T24 cells.
1.Introduction
In 2008, approximately 37500 new bladder cancer cases
were diagnosed worldwide [1]. In the United States, approx-
imately 68,810 people and 14,100 deaths from bladder
cancer were reported in 2008 alone [1]. According to
the Taiwan Department of Health annual reports 2009,
bladder cancer is 14th leading cause of cancer death in
Taiwanese men and about three persons per one hundred
thousand die annually from that. Today, bladder cancer is
usually treated with surgery, chemotherapy, and combina-
tion of chemotherapy and radiotherapy, but they are often2 Evidence-Based Complementary and Alternative Medicine
intolerable because of the strong systemic toxicity and local
irritation [2]. Therefore, the ﬁnding for a novel adjuvant
agent to treat bladder cancer that can reduce the recurrence
rate, decrease side eﬀects, and increase overall survival is
urgent. In the past ten years, investigators have focused
on plant food-derived phytochemicals to ﬁnd potential
anticancer drugs [3, 4]. Approximately 70% of the currently
approved anticancer drugs are derived from or based on
n a t u r a lp r o d u c t s[ 5]. Cucurbitacin E (molecular formula:
C32H44O8) is a natural ﬂavonoid found in Cucurbitaceae
but also presents in other plants [6–8] and traditional
Chinese herbal medicine such as Cucurbita pepo cv dayangua
[9]. Cucurbitacin E has been reported to exhibit bio-
logical activities, including antioxidant, anti-inﬂammatory,
and anticancer eﬀects [6, 9, 10]. Cucurbitacin E induced
cytotoxic eﬀects, including suppression of the proliferation
and induction of apoptosis in ovarian [11, 12], leukemia [13,
14], and pancreatic [15] cancer cell lines. Cucurbitacin E also
suppressedtumorangiogenesisthroughinteractingvascular-
endothelial-growth-factor-receptor-2-(VEGFR2-) mediated
Janus kinase 2 (Jak2)-signal transducer and activator of tra-
nscription 3 (STAT3) signals [9].
It is well documented that apoptosis plays an important
role in the maintenance of tissue homeostasis for the
elimination of excessive cells [16]. However, it is also well
known that the induction of apoptosis of cancer cells by
anticancer drugs such as etoposide, cisplatin, and paclitaxel
has been used for treatment of cancer in target cells [17–20].
Many reports have shown that numerous cytotoxic and DNA
damaging agents could arrest the cell cycle at the G1, S, or
G2/M phase and induce apoptotic cell death [21–23]w h i c h
is involved in downregulation of phosphorylated STAT3, an
oncogene that has a vital role at all stages of tumorigenesis
[15]. Therefore, the present study investigated the induction
of apoptosis by cucurbitacin E in human bladder cancer
cells, and we also attempted to clarify the possible signaling
pathways involved in cucurbitacin E-induced apoptosis. Our
results indicated cucurbitacin E induced G2/M phase arrest
and apoptosis in human bladder cancer T24 cells through
STAT3/p53/p21, Fas/CD95, and mitochondria-dependent
pathways.
2.MaterialandMethods
2.1. Chemicals and Reagents. Cucurbitacin E, dimethyl sul-
foxide (DMSO), propidium iodide (PI), 3-(4,5-Dimethylthi-
azol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), RNase
A, and Triton X-100 were purchased from Sigma-Aldrich
Corp. (St. Louis, MO, USA). All primary and secondary an-
tibodies were obtained from Santa Cruz Biotechnology Inc.
(SantaCruz,CA,USA).TheﬂuorescentprobeDiOC6 andall
culture media and reagents were purchased from Invitrogen
Life Technologies (Carlsbad, CA, USA).
2.2. Cell Culture. The human bladder cancer cell line (T24)
(transitional cell carcinoma) was purchased from the Food
Industry Research and Development Institute (Hsinchu,
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Figure 1: The chemical structure of cucurbitacin E and its eﬀects
of cell viability on human bladder cancer T24 cells. Cells were
treated with diﬀerent concentrations of cucurbitacin E for 24h
(a) and 48h (b) and then cells were harvested for calculated the
percentageofviablecellsasdescribedintheMaterialsandMethods.
Data are presented as mean ± S.D. in triplicate. a, P ≤ 0.05,
is signiﬁcant diﬀerent compared with the DMSO-treated control;
b, c and d, P ≤ 0.05, are signiﬁcant diﬀerent with 250, 500
and 1000nM of cucurbitacin E treatment, respectively, by one-way
ANOVA followed by Bonferroni’s test for multiple comparisons.
Taiwan) and was cultured with McCoy’s 5a medium supple-
mented with 10% FBS, 100 Units/mL penicillin, 100μg/mL
streptomycin, and 2mM L-glutamine at 37◦Cu n d e rah u -
midiﬁed 5% CO2 and 95% air at one atmosphere. The me-
dium was changed every 2 days [24].
2.3. Determinations of Cell Morphology and Viability. About
2 × 105 T24 cells/well were seeded into 12-well plates for
cell adherence with three wells for each concentration level.
Cucurbitacin E was individually added to the ﬁnal concen-
trations of 0, 250, 500, 1000, and 2000nM, respectively. In
control group, equal amount of 1% DMSO was added, while
in blank control group, only culture medium was added
to each well. In the end of incubation for 24 or 48h, cells
from each well were examined and photographed under a
phase-contrast microscope at 200× magniﬁcation and then
cell viability was determined using the MTT method, as
described previously [25, 26].
2.4. Cell Cycle Distribution and Phase Determination. The
cell cycle distribution and sub-G1 phase were analyzed byEvidence-Based Complementary and Alternative Medicine 3
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Figure 2: The eﬀects of cucurbitacin E on the G2/M phase arrest in T24 cells. Cells at a density of 2×105 cells per well were placed in 12-well
plates and then were treated with 1000nM cucurbitacin E for diﬀerent time periods (12, 24, or 48h). Cells were harvested for evaluating the
cell cycle distribution as described in the Materials and Methods. (a) The representative of proﬁles of DNA content; (b) the percentage of
cells in G0/G1, S, and G2/M phase in T24 cells. Data revealed a representative experiment in triplicate with similar results.
ﬂow cytometry, as described previously [27, 28]. A total of
2 × 105 T24 cells/well on 12-well plates were incubated with
1000nM cucurbitacin E or only with vehicle (DMSO, 1%
in culture media) for 0, 12, 24, and 48h. At the end of
incubation, the cells on each well were trypsinized, washed
with PBS, and ﬁxed with 70% ethanol overnight at −20◦C.
At the next day, all ﬁxed cells were from experimental and
control groups washed twice with PBS and then were stained
with PI-working solution (40μg/mL PI and 100μg/mL
RNaseAand0.1%TritonX-100)forcellularstainingatroom
temperature for 1h in the dark. Then all cells were analyzed
for cell cycle distribution and sub-G1 phase (apoptosis)
by ﬂow cytometry, as described previously [27, 28]. The
fractions of the cells in G0/G1, S, and G2/M phase were
analyzed using a FACSCalibur ﬂow cytometer (Becton-
Dickinson, FranklinLakes,NJ,USA),anddatawereanalyzed
with a ModFit LT program (Verity Software House Inc.,
Topsham, ME, USA).
2.5. Assessment of Apoptosis. Apoptotic cells were measured
with an Annexin V-FITC/PI detection kit (Invitrogen Life
Technologies). Approximately 2 × 105 cells in 12-well plates
per treatment or control samples (1000nM cucurbitacin E
for 12 and 24h) were harvested and analyzed by ﬂow cytom-
etry, as described previously [26, 29]. Annexin V-FITC is a
sensitive probe for identifying cells undergoing apoptosis as
phosphatidylserine (PS) exposure occurs early in the apop-
totic process. PI is excluded from live cells with intact plasma
membranes, but it is incorporated into nonviable cells.
2.6. CDK1 Kinase Activity. T24 cells were seeded onto
75cm2 tissue culture ﬂask and then treated with 0, 250,4 Evidence-Based Complementary and Alternative Medicine
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Figure 3: The eﬀects of cucurbitacin E on the STAT3 phosphorylation, cell cycle-regulated associated proteins, and CDK1 activity in T24
cells. Cells at 1 × 106 (cells/well) were placed in 6-well plates and then treated without and with 250, 500, and 1000nM of cucurbitacin E
for 24h. Thereafter, cells were harvested and total proteins were collected for western blot analysis to examine the changes of protein levels
of p-STAT, STAT, and p53 (a), p21, CDK1, and cyclin B1 (b) as well as CDK1 activity (c) as described in Materials and Methods. Each
value is mean ± S.D. of three experiments; a, P ≤ 0.05, is signiﬁcantly diﬀerent compared with control (0nM); b and c, P ≤ 0.05, reveal
signiﬁcantly diﬀerence compared with 250 and 500nM of cucurbitacin E, respectively (one-way ANOVA followed by Bonferroni’s test for
multiple comparisons).
500, and 1000nM of cucurbitacin E for 24h. Cells were
s u s p e n d e di naﬁ n a lv o l u m eo f0 . 2 m Lb u ﬀer containing
50mM Tris-HC1 (pH 7.5), 1mM phenylmethylsulfonyl
ﬂuoride, 50pg/mL leupeptin, 10mM 2-mercaptoethanol,
1mM MgCl 2, 2mM EGTA, 0.5mM dithiothreitol, 0.01%
Brij35, 25mM β-glycerophosphate, and 0.5M NaCl. Cell
suspensions were sonicated and centrifuged at 10,000×g
for 30min. CDK1 kinase activity condition was determined
by using MV Peptide (CDK1 kinase assay kit, Medical
& Biological Laboratories Co., Ltd., Nagoya, Japan) and
measuring OD492, as described previously [26, 30].
2.7. Assay of Mitochondrial Membrane Potential (ΔΨm). A
density of 2 × 105 T24 cells/well on 12-well plates was
maintained with 1000nM cucurbitacin E for 0, 4, 8, 12, 24,
and 48h, to determine the level of ΔΨm by ﬂow cytometry.
At the end of incubation, cells were harvested, washed twice
by PBS, and then resuspended in 500μLo fD i O C 6(1μmol/l)
for the level of ΔΨm. Subsequently, cells were maintained
at dark room for 30min at 37◦C and then all samples
were analyzed immediately by ﬂow cytometry, as described
previously [31, 32].
2.8. Detection of Cell Viability after Pretreatment with a
General Caspase Inhibitor. T24 cells at a density of 1 × 104
cells/100μL seeded in 96-well plates were preincubated with
or without 10μM of the general caspase inhibitor (Z-VAD-
FMK, R&D Systems, Minneapolis, MN, USA) for 2h before
cells were exposed to 1000nM cucurbitacin E for a 48-h
exposure. Thereafter, cells were determined for the viability
by using a MTT assay, as previously described [25, 26].
2.9. Western Blot Analysis for Protein Levels. T24 cells (1 ×
106/well)seededinto6-wellplatesweretreatedwith1000nM
cucurbitacin E or solvent control. Cells were harvested from
each treatment then were washed with cold PBS and then
scraped and washed twice by centrifugation at 1,000xg for
5min at 4 ◦C. All pellets were individually resuspendedEvidence-Based Complementary and Alternative Medicine 5
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Figure 4: The eﬀects of cucurbitacin E on the apoptotic death of T24 cells. Cells at a density of 2×105 cells/well were placed in 12-well plates
then were treated with 500 and 1000nM of cucurbitacin E for examining the morphological changes (a). Cells were incubated with 1000nM
cucurbitacinEfordiﬀerenttimeperiods(12,24,and48h),andthencellswereharvestedforevaluatingthesub-G1phase(apoptosis)byﬂow
cytometry (b). Cells were exposed to 1000nM cucurbitacin E for 12 and 24h, and then cells were harvested for determining the annexin V
positive/PI negative (apoptotic cells) as described in Materials and Methods. The results are shown as a mean ± SD (n = 3); a is signiﬁcantly
diﬀerent (P ≤ 0.05) compared to control; b and c represent signiﬁcant diﬀerence (P ≤ 0.05) compared with 1000nM cucurbitacin E for 12
and 24h, respectively, by one-way ANOVA followed by Bonferroni’s test for multiple comparisons.
in the PRO-PREP protein extraction solution (iNtRON
Biotechnology, Seongnam, Gyeonggi-Do, Korea) for 3h at
−20◦C, as described previously [33, 34]. The lysate from
each sample was collected by centrifugation at 12,000×gf o r
30min at 4◦C, and the supernatant was stored at −20◦C.
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) gels were used to separate the protein before
each sample was incubated with the primary antibodies
(Santa Cruz Biotechnology Inc.) followed by secondary
antibodies. These blots were then detected by ECL kit
(Millipore, Bedford, MA, USA) and autoradiography using
X-ray ﬁlm [27, 35]. Each PVDF membrane (Immobilon-
P; Millipore) was stripped and reported with anti-β-actin
antibody as the loading control for ensuring that equal
proteins were loaded [32, 36].
2.10. Statistical Analysis. A l lv a l u e sa r ee x p r e s s e da sm e a n±
standard deviation (S.D.) and performed in triplicate. One-
way ANOVA was used to compare the diﬀerence between
controlandconcentrationtreatmentsineachgroupfollowed
by Bonferroni’s multiple comparison tests. A P value of less
than 0.05 was considered to be statistically signiﬁcant.
3. Results
3.1. The Eﬀects of Cucurbitacin E on Cell Growth and Viability
of T24 Cells. The examined concentrations of cucurbitacin
E inhibited cell growth and induced cytotoxicity of T24
cells. Cells were treated with various concentrations (0,
250, 500, 1000, and 2000nM) of cucurbitacin E or 1%,
DMSO as a control for 24 and 48h. Percentage of the live
cells in each group was determined by MTT method. Our
data indicated that cucurbitacin E at the concentrations of
250–2000nM inhibited cell growth in a concentration- and
time-dependent manner (Figures 1(a) and 1(b)) with the
half maximal inhibitory concentration (IC50) of 1012.32 ±
10.6nM after a 48h treatment.
3.2. The Eﬀects of Cucurbitacin E on DNA Content of T24
Cells. Cell-cycledistributionofT24cellsaftertreatmentwith
1000nM cucurbitacin E for 12, 24, and 48h was measured
by ﬂow cytometry. Results were shown that the proﬁle
from ﬂow cytometry and BD CellQuest Pro software in the
number of cells in G2/M phase was increased after treatment
with 1000nM of cucurbitacin E for 24h (Figure 2(a)). The
number of cells in G2/M phase was increased from 19.4% to6 Evidence-Based Complementary and Alternative Medicine
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Figure 5: The eﬀects of a general caspase inhibitor (Z-VAD-FMK) on cucurbitacin E-induced cell viability and caspase cascades protein
levelsonT24cells.Cellswerepretreatedwith10μMZ-VAD-FMKandthenexposedto1000nMcucurbitacinEfor48h.Cellswereharvested
and determined for percentage of viable cells (a) and for evaluating the protein levels of caspase-8, -9, and -3 (b) as described in Materials
and Methods. Columns: mean (n = 3); bars: SD. a, P ≤ 0.05, is signiﬁcantly diﬀerent compared with untreated control; b, P ≤ 0.05,
shows signiﬁcant diﬀerence compared with 1000nM cucurbitacin E treatment group by one-way ANOVA followed by Bonferroni’s multiple
comparison test.
24.6%, 48.66% and 65.89% after 12, 24 and 48h treatments,
respectively and these eﬀects are time-dependent responses
(Figure 2(b)). These data suggest that the induction of G2/M
phase arrest accounts for the growth inhibitory eﬀects of
cucurbitacin E-treated T24 cells.
3.3. The Eﬀects of Cucurbitacin E on the Levels of STAT3,
p53, and p21 as well as G2/M Phase-Associated Protein Levels
in T24 Cells. To investigate the molecular mechanisms of
cucurbitacin E-induced G2/M phase arrest in T24 cells,
cucurbitacin E-treated cells determined the G2/M phase-
modulated relative protein levels. Results from western
blotting and CDK1 activity were shown in Figure 3.Ourd ata
indicated that the level of p53 was increased, and the level
of p-STAT3 was decreased, but the level of STAT3 was not
altered (Figure 3(a)) in cucurbitacin E-treated T24 cells. The
level of p21 was upregulated, but the levels of CDK1 and
cyclin B were downregulated, leading to induce G2/M phase
arrest. The CDK1 activity also was inhibited by cucurbitacin
E and this eﬀect is a dose-dependent manner (Figure 3(c)).
Based on these results, we suggest that cucurbitacin E-
increased G2/ Mp h a s ea r r e s ti nT 2 4c e l l sm i g h tb ei n v o l v e d
in STAT3/p53/p21 signaling.
3.4. The Eﬀects of Cucurbitacin E on Morphological Obser-
vation and Apoptosis in T24 Cells. Cells were exposed to
0 (control), 500, and 1000nM of cucurbitacin E for 48h,
and then examined and photographed by a phase-contrast
microscope. Moreover, cells were treated with 1000nM
cucurbitacin E for 0, 12, 24, or 48h and then assayed
the percentage of sub-G1 phase by ﬂow cytometry. The
results shown in Figure 4(a) indicated that cucurbitacin E
induced morphological changes such as membrane bleb-
bing, reduction in cell volume, and these eﬀects are dose-
dependent manners (Figure 4(a)). Figure 4(b) also shows
that cucurbitacin E induced sub-G1 phase (apoptosis) inEvidence-Based Complementary and Alternative Medicine 7
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Figure 6: The eﬀects of cucurbitacin E on mitochondrial membrane potential (ΔΨm) in T24 cells. Cells at a density of 2 × 105 cells/well
placed in 12-well plates were treated with 1000nM cucurbitacin E for 0, 4, 8, 12, 24, and 48h and then harvested for measuring the level
of ΔΨm as described in Materials and Methods. (a) The representative of proﬁle of ΔΨm, and (b) the levels of ΔΨm quantiﬁed form BD
CellQuest Pro software. Each experiment was done with triple sets: a, P ≤ 0.05, shows signiﬁcant diﬀerence compared with 0h treatment;
b, c, and d, P ≤ 0.05, are signiﬁcantly diﬀerent compared to cucurbitacin E treatment for 4, 8, and 12h, respectively, by one-way ANOVA
followed by Bonferroni’s multiple comparison test.
cell cycle distribution that indicated that cucurbitacin E
induced apoptosis, and this eﬀect is a time-dependent
manner. Apoptotic cells were also conﬁrmed by Annexin
V/PIstainingassayincucurbitacinE-treatedT24cellsasseen
in Figure 4(c).
3.5. The Eﬀects of Cucurbitacin E on Protein Levels of Caspase-
3, -8, and -9 in T24 Cells. To investigate if cucurbitacin E
induces apoptosis in T24 cells through caspases-dependent
pathway, cells were pretreated with a general caspase
inhibitor (Z-VAD-FMK) and then exposed to cucurbitacin
E for 48h treatment. Results indicate that Z-VAD-FMK is
able to protect against cucurbitacin E-reduced cell viability
in T24 cells. Also, our results from western blotting indicated
that the levels of active form of caspase-3, -8, and -9 were
stimulated in cucurbitacin E-treated T24 cells (Figure 5(b)).
This study suggests that cucurbitacin E-induced apoptosis
of T24 cells is mediated via caspase cascade-dependent
pathway.
3.6. The Eﬀects of Cucurbitacin E on Mitochondrial Mem-
brane Potential (ΔΨm)o fT 2 4C e l l s .To investigate whether
mitochondrial dysfunction is involved in cell apoptosis
induced by cucurbitacin E in T24 cells, cells were exposed to
cucurbitacin E for 0, 4, 8, 12, 24, and 48h and subsequently
harvested for determination of the level of ΔΨm by ﬂow
cytometry. Results shown in Figures 6(a) and 6(b) indicated
that cucurbitacin E decreased the level of ΔΨm and this eﬀect
is a time-dependent manner.
3.7. The Eﬀects of Cucurbitacin E on Apoptosis-Associated Pro-
tein Levels in T24 Cells. It is well known that mitochondria-
mediated activation of caspase-9 and caspase-3 involved the
releases of cytochrome c and AIF [37, 38]. The treatment
with cucurbitacin E increased the levels of cytochrome
c, Apaf-1, AIF, truncated BID (Figure 7(a)), and Fas
(Figure 7(b)) in cucurbitacin E-treated T24 cells. These data
suggest that the increased levels of Fas/CD95, cytochrome c,
Apaf-1, and truncated BID led to the activation of caspase-8,
caspase-9, and caspase-3 (Figure 5(b)). Hence, cucurbitacin8 Evidence-Based Complementary and Alternative Medicine
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Figure 7: The eﬀects of cucurbitacin E on the apoptosis-associated
proteins in T24 cells. Cells (1 × 106/well) seeded into 6-well
plates were treated with 1000nM cucurbitacin and were treated
with diﬀerent concentrations of cucurbitacin E for 48h and then
harvested for western blotting to examine the protein levels of
cytochrome c, Apaf-1, BID, and truncated BID (a), Fas and FasL
(b) as described in Materials and Methods.
E-provoked apoptosis in T24 cells is mediated through the
Fas/CD95 and mitochondria-dependent pathways.
4. Discussion
It is well known that the resistant to current therapies is one
of the poor prognostic outcomes of human bladder cancer
and it is the leading cause of cancer-related death [39, 40].
Currently, the successful treatment with chemotherapeutic
agents is based on these agents to trigger cell death in tumor
cells [41–43]. Until now, investigators have been focusing on
the novel inducers of apoptosis to provide a new therapeutic
approach for cancer patients and some of the compounds for
treatment of cancer are from natural products [44–46].
Results showed that cucurbitacin E induced G2/M phase
arrest (Figure 2) in T24 cells. The protein levels of phospho-
STAT3, CDK1, and cyclin B were decreased, and the levels
of p53 and p21 were increased in cucurbitacin E-treated
T24 cells in a time-dependent manner (Figures 3(a) and
3(b)). Furthermore, curcumin E also inhibited the CDK1
activity in T24 cells (Figure 3(c)). It is reported that activated
STAT3 is formed through downregulating p53 level and
aﬀects the p53 promoter in in vitro and in vivo studies
[47]. Moreover, CDKs regulate the cell-cycle progression in
mammalian cells [48, 49]. In the G2/M phase progression
which is regulated with CDK1 and CDK2 kinases that are
activated primarily in association with cyclins A and B
[50]; it is reported that distributing cell-cycle progression
by alterations in cell cycle-related protein expression plays
important roles in the proliferation of cancer cells [50, 51].
Therefore, we suggest that alterations in STAT3/p21/p53
signaling and G2/M phase-associated protein levels occurred
in cucurbitacin E-treated T24 cells. This is also in agreement
with other reports addressing that inhibitory eﬀect of
STAT3leveloncucurbitacinEandtriterpene-derivednatural
products treated human tumor cells and umbilical vascular
endothelial cells in vitro [9, 11, 51].
Our results also showed that cucurbitacin E induced
apoptotic death of T24 cells and this eﬀect is a dose-
and time-dependent response (Figure 4). Apoptosis is a
programmed cell death which is a multiple regulated process
which can be divided into the caspases and mitochondrial
signalingpathways[52,53].CucurbitacinEtreatmentinT24
cells promoted the activations of caspase-8, -9, and -3 in a
dose-dependent manner (Figure 5(b)). Otherwise, cells were
pretreated with a general caspase inhibitor (Z-VAD-FMK)
and exposed to cucurbitacin E, leading to increase the
percentage of viable cells when compared to the cucurbitacin
E-treated only cells (Figure 5(a)). The data indicated that
the activation of caspase cascade is involved in cucurbitacin
E-induced cell death
Result from Figures 6(a) and 6(b) indicated that cucur-
bitacin E decreased the level of ΔΨm in a time-dependent
response. Bcl-2 family proteins (antiapoptotic and proapop-
totic proteins) have been reported to regulate cytochrome c
release from mitochondria [53, 54]. Our results also showed
that cucurbitacin E promoted the level of cytochrome c
(released from mitochondria) (Figure 7(a)). Cucurbitacin
increased the levels of truncated BID which is related to the
dysfunction of mitochondria (Figure 7(a)). Figure 7(a) also
shows an increase in the level of AIF which is released from
mitochondria. Based on these observations, we may suggest
that cucurbitacin-induced apoptosis of T24 cell is carried
out through the Fas/CD95 and mitochondrial signaling
pathways.
Inconclusion,cucurbitacinEdecreasedthepercentageof
viable T24 cells through the cell cycle arrest and induction
of apoptosis in human bladder T24 cancer cells in vitro.
Cucurbitacin E-induced G2/M phase arrest was associated
with the inhibitions of phosphorylation STAT3, promotion
of p53 and p21, and reduction of CDK1 and cyclin B.
Cucurbitacin E-induced apoptosis was accompanied with
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p-STAT3 ↓
p53 ↑
p21 ↑
CDK 1 ↓
Cyclin B ↓
G2/M phase arrest
Cytochrome c ↑
Apaf-1 ↑
Caspase-9 ↑
BID
ΔΨm ↓
tBID ↑
Caspase-3 ↑
Cell apoptosis
Caspase-8 ↑
AIF ↑
Fas/CD95 ↑
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Figure 8: The possible signaling pathways for cucurbitacin E-induced G2/M phase arrest through STAT3/p53/p21 signaling and apoptosis
via Fas/CD95 and mitochondria-dependent pathways in human bladder cancer T24 cells.
then led to cytochrome c release from mitochondria and
promoted the activations caspase-8, caspase-9, and caspase-
3, leading to apoptosis of T24 cells. The proposed signaling
pathways can be seen in Figure 8.
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